Pneumocystis pneumonia in French intensive care units in 2013–2019: mortality and immunocompromised conditions

Toufik Kamel,Thierry Boulain

DOI: https://doi.org/10.1186/s13613-024-01309-y

IF: 10.318

2024-05-25

Annals of Intensive Care

Abstract:The recent epidemiology of Pneumocystis pneumonia (PCP) requiring intensive care unit (ICU) admission and the associated spectrum of immunocompromising conditions are poorly described.

critical care medicine

What problem does this paper attempt to address?

Trends in the Epidemiology of Pneumocystis Pneumonia in Immunocompromised Patients without HIV Infection

Ting Xue,Xiaomei Kong,Liang Ma

DOI: https://doi.org/10.3390/jof9080812

2023-07-31

Abstract:The increasing morbidity and mortality of life-threatening Pneumocystis pneumonia (PCP) in immunocompromised people poses a global concern, prompting the World Health Organization to list it as one of the 19 priority invasive fungal diseases, calling for increased research and public health action. In response to this initiative, we provide this review on the epidemiology of PCP in non-HIV patients with various immunodeficient conditions, including the use of immunosuppressive agents, cancer therapies, solid organ and stem cell transplantation, autoimmune and inflammatory diseases, inherited or primary immunodeficiencies, and COVID-19. Special attention is given to the molecular epidemiology of PCP outbreaks in solid organ transplant recipients; the risk of PCP associated with the increasing use of immunodepleting monoclonal antibodies and a wide range of genetic defects causing primary immunodeficiency; the trend of concurrent infection of PCP in COVID-19; the prevalence of colonization; and the rising evidence supporting de novo infection rather than reactivation of latent infection in the pathogenesis of PCP. Additionally, we provide a concise discussion of the varying effects of different immunodeficient conditions on distinct components of the immune system. The objective of this review is to increase awareness and knowledge of PCP in non-HIV patients, thereby improving the early identification and treatment of patients susceptible to PCP.
Characteristics and Prognosis Factors of Pneumocystis jirovecii Pneumonia According to Underlying Disease: A Retrospective Multicenter Study

Romain Lécuyer,Nahéma Issa,Fabrice Camou,Rose-Anne Lavergne,Frederic Gabriel,Florent Morio,Emmanuel Canet,François Raffi,David Boutoille,Anne Cady,Marie Gousseff,Yoann Crabol,Antoine Néel,Benoît Tessoulin,Benjamin Gaborit,PRONOCYSTIS Study Group,Francois Raffi,Charlotte Biron,Maeva Lefebvre,Benjamin Jean Gaborit,Paul Le Turnier,Colin Deschanvres,Raphael Lecomte,Marie Chauveau,Antoine Asquier-Khati,Patrice Le Pape,Fakhri Jeddi,Stéphane Corvec,Pascale Bemer,Jocelyne Caillon,Aurélie Guillouzouic,Anne-Gaëlle Leroy,Karim Lakhal,Raphaël Cinotti,Antoine Roquilly,Jean Reignier Emmanuel Canet,François Xavier Blanc,Cédric Bretonniere,Paul Morin,Olivier Guisset,Gaelle Mourissoux,Isabelle Accoceberry,Noémie Coron,Laurence Delhaes,Sébastien Imbert,Maxime Lefranc,Florian Lussac-Sorton,Amandine Rougeron,Grégory Corvaisier,Florent Lautredoux,Myriam Auger,Pascal Pouedras

DOI: https://doi.org/10.1016/j.chest.2024.01.015

IF: 9.6

Chest

Abstract:Background: Pneumocystis jirovecii pneumonia (PcP) remains associated with high rates of mortality, and the impact of immunocompromising underlying disease on the clinical presentation, severity, and mortality of PcP has not been adequately evaluated. Research question: Does the underlying disease and immunosuppression causing PcP impact the outcome and clinical presentation of the disease? Study design and methods: In this multicenter retrospective observational study, conducted from January 2011 to December 2021, all consecutive patients admitted with a proven or probable diagnosis of PcP according to the European Organisation for Research and Treatment of Cancer consensus definitions were included to assess the epidemiology and impact of underlying immunosuppressive diseases on overall and 90-day mortality. Results: Overall, 481 patients were included in the study; 180 (37.4%) were defined as proven PcP and 301 (62.6%) were defined as probable PcP. Patients with immune-mediated inflammatory diseases (IMIDs) or solid tumors had a statistically poorer prognosis than other patients with PcP at day 90. In multivariate analysis, among the HIV-negative population, solid tumor underlying disease (OR, 5.47; 95% CI, 2.16-14.1; P < .001), IMIDs (OR, 2.19; 95% CI, 1.05-4.60; P = .037), long-term corticosteroid exposure (OR, 2.07; 95% CI, 1.03-4.31; P = .045), cysts in sputum/BAL smears (OR, 1.92; 95% CI, 1.02-3.62; P = .043), and SOFA score at admission (OR, 1.58; 95% CI, 1.39-1.82; P < .001) were independently associated with 90-day mortality. Prior corticotherapy was the only immunosuppressant associated with 90-day mortality (OR, 1.67; 95% CI, 1.03-2.71; P = .035), especially for a prednisone daily dose ≥ 10 mg (OR, 1.80; 95% CI, 1.14-2.85; P = .010). Interpretation: Among patients who were HIV-negative, long-term corticosteroid prior to PcP diagnosis was independently associated with increased 90-day mortality, specifically in patients with IMIDs. These results highlight both the needs for PcP prophylaxis in patients with IMIDs and to early consider PcP curative treatment in severe pneumonia among patients with IMIDs.
Severe Community-Acquired Pneumonia in Immunocompromised Patients

Dara Chean,Camille Windsor,Antoine Lafarge,Thibault Dupont,Sabrine Nakaa,Livia Whiting,Adrien Joseph,Virginie Lemiale,Elie Azoulay

DOI: https://doi.org/10.1055/s-0043-1778137

2024-01-25

Seminars in Respiratory and Critical Care Medicine

Abstract:Due to higher survival rates with good quality of life, related to new treatments in the fields of oncology, hematology, and transplantation, the number of immunocompromised patients is increasing. But these patients are at high risk of intensive care unit admission because of numerous complications. Acute respiratory failure due to severe community-acquired pneumonia is one of the leading causes of admission. In this setting, the need for invasive mechanical ventilation is up to 60%, associated with a high hospital mortality rate of around 40 to 50%. A wide range of pathogens according to the reason of immunosuppression is associated with severe pneumonia in those patients: documented bacterial pneumonia represents a third of cases, viral and fungal pneumonia both account for up to 15% of cases. For patients with an undetermined etiology despite comprehensive diagnostic workup, the hospital mortality rate is very high. Thus, a standardized diagnosis strategy should be defined to increase the diagnosis rate and prescribe the appropriate treatment. This review focuses on the benefit-to-risk ratio of invasive or noninvasive strategies, in the era of omics, for the management of critically ill immunocompromised patients with severe pneumonia in terms of diagnosis and oxygenation. Article published online: 24 January 2024 © 2024. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

respiratory system,critical care medicine
Pneumocystis jirovecii pneumonia in non-HIV patients: need for a more extended prophylaxis

Léo Sauvat,Laure Denis,Céline Nourrisson,Philippe Poirier,Marc Ruivard,Guillaume Le Guenno

DOI: https://doi.org/10.3389/fmed.2024.1414092

IF: 3.9

2024-06-26

Frontiers in Medicine

Abstract:Background Pneumocystis jirovecii pneumonia (PCP) has a significant mortality rate for non-HIV immunocompromised patients. Prevention is primarily based on combined trimethoprim and sulfamethoxazole (TMP-SMX) but guidelines on pneumocystosis prophylaxis are scattered and not consensual. Objectives This study aims to describe PCP in non-HIV patients and to review case by case the prior indication of prophylaxis according to specific guidelines. We included patients with confirmed diagnosis of PCP admitted to one university hospital from 2007 to 2020. Prior indication for pneumocystis prophylaxis was assessed according to the specific guidelines for the underlying pathology or treatment. Results Of 150 patients with a medical diagnosis of PCP, 78 were included. Four groups of underlying pathologies were identified: hematological pathologies (42%), autoimmune diseases (27%), organ transplantation (17%), and other pathologies at risk of PCP (14%). A small subgroup of 14 patients (18%) had received a prior prescription of pneumocystis prophylaxis but none at the time of the episode. Transfer to intensive care was necessary for 33 (42%) patients, and the mortality rate at 3 months was 20%. According to international disease society guidelines, 52 patients (59%) should have been on prophylaxis at the time of the pneumocystis episode. Lowest compliance with guidelines was observed in the hematological disease group for 24 patients (72%) without prescription of indicated prophylaxis. Conclusion Infectious disease specialists should draw up specific prophylactic guidelines against pneumocystis to promote a better prevention of the disease and include additional criteria in their recommendations according to individual characteristics to prevent fatal cases.

medicine, general & internal
Pneumocystis pneumonia in intensive care: clinical spectrum, prophylaxis patterns, antibiotic treatment delay impact, and role of corticosteroids. A French multicentre prospective cohort study

Toufik Kamel,Ralf Janssen-Langenstein,Quentin Quelven,Jonathan Chelly,Xavier Valette,Minh-Pierre Le,Jeremy Bourenne,Denis Garot,Pierre Fillatre,Marie Labruyere,Nicholas Heming,Fabien Lambiotte,Jean-Baptiste Lascarrou,Olivier Lesieur,Konstantinos Bachoumas,Alexis Ferre,Eric Maury,Ludivine Chalumeau-Lemoine,David Bougon,Damien Roux,Olivier Guisset,Remi Coudroy,Thierry Boulain,Auchabie Johann,Beuret Pascal,Darreau Cédric,Desmeulles Isabelle,Guervilly Christophe,Hong Tuan Ha Vivien,Jochmans Sébastien,Jozwiak Mathieu,Louis Guillaume,Navellou Jean-Christophe,Neuville Mathilde,Pichon Nicolas,Sagnier Anne,Schnell David,on behalf of the PCP-MULTI Study group

DOI: https://doi.org/10.1007/s00134-024-07489-2

IF: 38.9

2024-06-04

Intensive Care Medicine

Abstract:Severe Pneumocystis jirovecii pneumonia (PJP) requiring intensive care has been the subject of few prospective studies. It is unclear whether delayed curative antibiotic therapy may impact survival in these severe forms of PJP. The impact of corticosteroid therapy combined with antibiotics is also unclear.

critical care medicine
Outcome and prognostic factors of Pneumocystis jirovecii pneumonia in immunocompromised adults: a prospective observational study

Benjamin Jean Gaborit,Benoit Tessoulin,Rose-Anne Lavergne,Florent Morio,Christine Sagan,Emmanuel Canet,Raphael Lecomte,Paul Leturnier,Colin Deschanvres,Lydie Khatchatourian,Nathalie Asseray,Charlotte Garret,Michael Vourch,Delphine Marest,François Raffi,David Boutoille,Jean Reignier

DOI: https://doi.org/10.1186/s13613-019-0604-x

2019-11-27

Abstract:Background: Pneumocystis jirovecii pneumonia (PJP) remains a severe disease associated with high rates of invasive mechanical ventilation (MV) and mortality. The objectives of this study were to assess early risk factors for severe PJP and 90-day mortality, including the broncho-alveolar lavage fluid cytology profiles at diagnosis. Methods: We prospectively enrolled all patients meeting pre-defined diagnostic criteria for PJP admitted at Nantes university hospital, France, from January 2012 to January 2017. Diagnostic criteria for PJP were typical clinical features with microbiological confirmation of P. jirovecii cysts by direct examination or a positive specific quantitative real-time polymerase chain reaction (PCR) assay. Severe PJP was defined as hypoxemic acute respiratory failure requiring high-flow nasal oxygen with at least 50% FiO2, non-invasive ventilation, or MV. Results: Of 2446 respiratory samples investigated during the study period, 514 from 430 patients were positive for P. jirovecii. Of these 430 patients, 107 met criteria for PJP and were included in the study, 53 (49.5%) patients had severe PJP, including 30 who required MV. All patients were immunocompromised with haematological malignancy ranking first (n = 37, 35%), followed by solid organ transplantation (n = 27, 25%), HIV-infection (n = 21, 20%), systemic diseases (n = 13, 12%), solid tumors (n = 12, 11%) and primary immunodeficiency (n = 6, 8%). By multivariate analysis, factors independently associated with severity were older age (OR, 3.36; 95% CI 1.4-8.5; p < 0.05), a P. jirovecii microscopy-positive result from bronchoalveolar lavage (BAL) (OR, 1.3; 95% CI 1.54-9.3; p < 0.05); and absence of a BAL fluid alveolitis profile (OR, 3.2; 95% CI 1.27-8.8; p < 0.04). The 90-day mortality rate was 27%, increasing to 50% in the severe PJP group. Factors independently associated with 90-day mortality were worse SOFA score on day 1 (OR, 1.05; 95% CI 1.02-1.09; p < 0.001) whereas alveolitis at BAL was protective (OR, 0.79; 95% CI 0.65-0.96; p < 0.05). In the subgroup of HIV-negative patients, similar findings were obtained, then viral co-infection were independently associated with higher 90-day mortality (OR, 1.25; 95% CI 1.02-1.55; p < 0.05). Conclusions: Older age and P. jirovecii oocysts at microscopic examination of BAL were independently associated with severe PJP. Both initial PJP severity as evaluated by the SOFA score and viral co-infection predicted 90-day mortality. Alveolitis at BAL examination was associated with less severe PJP. The pathophysiological mechanism underlying this observation deserves further investigation.
Clinical characteristics of Pneumocystis carinii pneumonia in immunocompromised patients

孙禾,吴晓东,韩蕙泽,施毅,李强

DOI: https://doi.org/10.3760/cma.j.cn311365-20190903-00279

2020-01-01

Abstract:Objective:To understand the clinical characteristics of Pneumocystis carinii pneumonia (PCP) in immunocompromised patients. Methods:Clinical data of 15 patients with PCP hospitalized in Shanghai East Hospital, Tongji University from March 2018 to March 2019 were retrospectively analyzed. Clinical manifestations, laboratory index examinations, imaging characteristics, comorbidities, treatment and outcome were observed.Results:Among the 15 cases, 11 were cases with hematological malignancies and four cases received allogenetic hematopoietic stem cell transplantation (AHSCT). The onset time was (5.82±2.33) months after transplantation. Chest computed tomography (CT) of all 15 patients showed diffuse ground glass-like exudation of the lungs surrounding hilar. Peripheral blood CD4 + T cell count decreased to (135.17±74.83)/μL and oxygenation index to (188.47±41.03) mmHg(1 mmHg=0.133 kPa), while lactic acid dehydrogenase (LDH) elevated to (576.18±228.01) U/L.Levels of 1, 3-β-D-glucan in serum and bronchoalveolar lavage fluid (BALF) increased to (1 862.81±157.73) ng/L and (1 216.97±957.16) ng/L, respectively. Metagenomic next-generation sequencing (mNGS) of BALF showed that the numbers of sequence of Pneumocystis carinii were 120 to 14 383. There were nine patients co-infected with cytomegalovirus (CMV), four patients with Epstein-Barr virus, and two patients with gram-negative bacilli. All the patients received compound sulfamethoxazole and caspofungin treatment, and 13 cases improved and two died. Conclusions:Patients with hematological malignancies and AHSCT are at high-risk of PCP. Serum counts of CD4 + T cells decrease, while serum levels of LDH and 1, 3-β- D-glucan increase.mNGS is valuable for early diagnosis.
Epidemiology, Clinical Characteristics, and Diagnostic Testing Practices for Pneumocystis Pneumonia–Associated Hospitalizations, United States, 2019–2022

Kaitlin Benedict,James Baggs,Jeremy A W Gold

DOI: https://doi.org/10.1093/ofid/ofae054

2024-01-31

Open Forum Infectious Diseases

Abstract:Abstract Among 9196 hospitalizations involving Pneumocystis pneumonia, those without HIV had higher in-hospital mortality (24.3% vs 10.5%, P < .001) when compared with those with HIV. These findings underscore the continued importance of Pneumocystis pneumonia clinical awareness and the need for comprehensive prophylaxis guidance, particularly for certain patients without HIV who are immunosuppressed.

immunology,infectious diseases,microbiology
Clinical course and prognostic factors of Pneumocystis pneumonia with respiratory failure in non-HIV patients

Jun Li,Xiangdong Mu,Haichao Li,Xinmin Liu

DOI: https://doi.org/10.3389/fcimb.2024.1380494

2024-07-10

Abstract:Background: Compared with Human Immunodeficiency Virus (HIV) patients, non-HIV patients with Pneumocystis pneumonia (PCP) have more rapid onset, more rapid progression, and higher mortality. Objectives: To investigate the predictive value of variables obtained upon hospital admission for in-hospital death and 90-day outcomes in non-HIV-PCP patients with respiratory failure (RF). Methods: This was a single center retrospective study in a tertiary care institution over 15 years. It included all adults inpatients (≥18 years old) with laboratory confirmed non-HIV-PCP with RF who were discharged or died from Peking University First Hospital between April 1st, 2007 and November 1st, 2022. Epidemiological, clinical, laboratory, imaging and outcome data were collected from patient records. Results: In this study, a total of 146 non-HIV-PCP patients with RF were included. There were 57 patients (39%) died during hospitalization, 44 patients (53%) died in Intensive care unit (ICU). A total of 137 patients completed 90 days of follow-up, of which 58 (42.3%) died. The multivariable regression analysis revealed that a CD8+ T cell count <115/μl (P=0.009), bronchoalveolar lavage fluid (BALF)-neutrophil percentage ≥50% (P=0.047), the time from corticosteroids withdrawal to symptom onset ≤5 days (P=0.012), and the time from visit to initiation of sulfonamides ≥2 days (P=0.011) were independent risk factors for in-hospital death. Furthermore, a CD8+ T cell count < 115/μl (P=0.001) and the time from visit to initiation of sulfonamides therapy ≥2 days (P=0.033) was independently associated with 90-day all-cause death. Conclusions: A low CD8+ T cell count in peripheral blood, a high percentage of BALF-neutrophils, a short time from corticosteroids withdrawal to symptom onset, and a long time from visit to initiation of sulfonamides are associated with poor prognosis in non-HIV-PCP patients with RF.
Community-acquired Klebsiella pneumoniae pneumonia in ICU: a multicenter retrospective study

Vincent Grosjean,Simon B. Gressens,Tài Pham,Stéphane Gaudry,Hafid Ait-Oufella,Nicolas De Prost,Julien Mayaux,Emmanuel Guerot,Véronique Leflon-Guibout,Noémie Mayer,Frédéric Bert,Nathalie Gault,Clément R. Massonnaud,Damien Roux

DOI: https://doi.org/10.1186/s13613-024-01269-3

IF: 10.318

2024-05-02

Annals of Intensive Care

Abstract:Alongside the recent worldwide expansion of hypervirulent Klebsiella pneumoniae (KP) infections, the available literature regarding cases of community acquired pneumonias (KP-CAP) remains scarce but reports a strikingly high and early mortality. We performed a retrospective multicenter study (7 ICU in France) between 2015 and 2019, comparing prognosis and severity of KP-CAP versus Streptococcus pneumoniae - CAP (SP-CAP).

critical care medicine
Hospital Burden of All-Cause Pneumonia and Nonbacteremic Pneumococcal Pneumonia in Adults in France Between 2013 and 2019

Ayman Sabra,Marie Bourgeois,Emmanuelle Blanc,Stephane Fievez,Jennifer Moïsi,Gwenaël Goussiaume,Magali Lemaitre,Laurence Watier,Nicolas Coulombel,Julien Tréhony,Aurore Tricotel,Yasmine Baghdadi,Muriel S Fartoukh

DOI: https://doi.org/10.1093/ofid/ofae349

2024-06-28

Open Forum Infectious Diseases

Abstract:Abstract Background Community-acquired pneumonia (CAP) is associated with significant morbidity and mortality. The study objective was to describe the hospital burden of pneumonia in the adult population in France. Methods This retrospective study was conducted from the National Health Insurance Database. All hospitalizations for pneumonia (all-cause) between 2013 and 2019 were included. Different risk categories for patients were established based on pneumococcal vaccine recommendations by French health authorities. Results A total of 2 199 240 episodes of CAP were registered over the study period (annual mean, 314 177 [standard deviation, 17 818.6]); 75% occurred in patients aged ≥65 years, among whom 47% were not classified in the moderate- or high-risk categories recommended for French pneumococcal vaccination. The incidence of CAP increased with age (117.9, 395.3, and 1916.7 per 100 000 for the age groups 18–49, 50–64, and ≥65 years, respectively, in 2019). Furthermore, being at risk of pneumococcal disease resulted in more severe outcomes, including longer episode duration (mean, 14 days in low-risk vs 17 days in high-risk patients) and higher risk of referral to critical care units (from 20% to 27%), of rehospitalization up to 180 days (from 39% to 67%), of in-hospital death (from 12% to 19%), and of 1-year mortality (from 26% to 49%). Conclusions This study establishes the incidence of CAP in adults in France, describes the significant burden of disease, and highlights the need for better prevention policies.

immunology,infectious diseases,microbiology
Incidence, caractéristiques et survie des patients présentant une pneumocystose en oncologie solide

Alexandre Peinoit,Léa Muzellec,Estelle Neveu,Tony Marchand,Julien Edeline,Charles Ricordel,Xavier Choderlos De Laclos

DOI: https://doi.org/10.1016/j.bulcan.2024.04.011

IF: 1.318

2024-06-06

Bulletin du Cancer

Abstract:Résumé Introduction La pneumocystose pulmonaire induit des pneumopathies interstitielles notamment chez les patients atteints de cancer solide. Les objectifs de cette étude sont de préciser son incidence, qui reste méconnue, d'identifier les patients à risque ainsi que les facteurs pronostiques. Méthodes Les données des patients atteints de cancer solide et de pneumocystose pulmonaire ont été recueillies rétrospectivement du 1 er janvier 2014 au 31 décembre 2019 dans deux centres hospitaliers Rennais. L'incidence a été estimée via le modèle de Poisson. Les données de survie ont été estimées via la méthode de Kaplan-Meier et du test du Log-rank. Un modèle de Cox multivarié a été réalisé pour identifier les facteurs de risque de décès. Résultats Les incidences de la pneumocystose pulmonaire chez les patients présentant un cancer métastatique recevant un traitement systémique parentéral, sont respectivement de 198 et 349 cas pour 100 000 patients par an dans ces deux centres. Les patients étaient en majorité traités par corticothérapie et chimiothérapie au moment de la pneumocystose pulmonaire. Le taux de mortalité des patients atteints de pneumocystose pulmonaire est de 38 %. La survie globale médiane était de 2,7 mois. Les facteurs de risques de décès sont une corticothérapie supérieure à 20 mg, en équivalent de prednisone, par jour et la chimiothérapie. Discussion La pneumocystose pulmonaire est rare mais non exceptionnelle et de mauvais pronostic en oncologie solide. Elle survient fréquemment chez les patients traités par corticoïdes au long cours. Une meilleure information des oncologues semble nécessaire pour discuter une prophylaxie dès qu'une corticothérapie est prescrite pendant plusieurs semaines. Summary Introduction Pulmonary pneumocystis causes interstitial lung disease, particularly in patients with solid cancers. The aim of this study is to clarify its incidence, which remains poorly understood, and to identify patients at risk and prognostic factors. Methods Data on patients with solid tumors and pulmonary pneumocystis were retrospectively collected from January 1, 2014 to December 31, 2019 in two hospitals in Rennes. Incidence was estimated via the Poisson model. Survival data were estimated using Kaplan-Meier method and Log-rank test. A multivariate Cox model was performed to identify risk factors for death. Results The incidences of pulmonary pneumocystis in metastatic cancer patients receiving parenteral systemic therapy are 198 and 349 cases per 100,000 patients per year in these two centers, respectively. Most patients were being treated with corticosteroids and chemotherapy at the time of pulmonary pneumocystis. The mortality rate for patients with pulmonary pneumocystis is 38%. Median overall survival was 2,7 months. Risk factors for death are corticotherapy greater than 20 mg, prednisone equivalent, daily and chemotherapy. Discussion Pulmonary pneumocystis pneumonia is rare but not exceptional and has a poor prognosis in solid oncology. It frequently occurs in patients treated with long-term corticosteroids. Oncologists need to be better informed to discuss prophylaxis whenever corticosteroids are prescribed for several weeks.

oncology
Impact of direct ICU admission of pneumococcal meningitis in France: a retrospective analysis of a French medico-administrative (PMSI) database

Michael Thy,Claire Dupuis,Arthur Mageau,Bruno Mourvillier,Lila Bouadma,Stéphane Ruckly,Anne Perozziello,Andrey Strukov,Damien Van-Gysel,Etienne de Montmollin,Romain Sonneville,Jean-François Timsit

DOI: https://doi.org/10.1186/s13613-023-01239-1

IF: 10.318

2024-01-28

Annals of Intensive Care

Abstract:Current guidelines for adult patients with pneumococcal meningitis (PM) recommend initial management in intermediate or intensive care units (ICU), but evidence to support these recommendations is limited. We aimed to describe ICU admission practices of patients with PM.

critical care medicine
Pneumocystis jirovecii in Patients With Cystic Fibrosis: A Review

Pierre Bonnet,Solène Le Gal,Enrique Calderon,Laurence Delhaes,Dorothée Quinio,Florence Robert-Gangneux,Sophie Ramel,Gilles Nevez

DOI: https://doi.org/10.3389/fcimb.2020.571253

2020-09-29

Abstract:Pneumocystis pneumonia (PCP) remains the most frequent AIDS-defining illness in developed countries. This infection also occurs in non-AIDS immunosuppressed patients, e.g., those who have undergone an organ transplantation. Moreover, mild Pneumocystis jirovecii infections related to low pulmonary fungal burden, frequently designated as pulmonary colonization, occurs in patients with chronic pulmonary diseases, e.g., cystic fibrosis (CF). Indeed, this autosomal recessive disorder alters mucociliary clearance leading to bacterial and fungal colonization of the airways. This mini-review compiles and discusses available information on P. jirovecii and CF. It highlights significant differences in the prevalence of P. jirovecii pulmonary colonization in European and Brazilian CF patients. It also describes the microbiota associated with P. jirovecii in CF patients colonized by P. jirovecii. Furthermore, we have described P. jirovecii genomic diversity in colonized CF patients. In addition of pulmonary colonization, it appears that PCP can occur in CF patients specifically after lung transplantation, thus requiring preventive strategies. In other respects, Pneumocystis primary infection is a worldwide phenomenon occurring in non-immunosuppressed infants within their first months. The primary infection is mostly asymptomatic but it can also present as a benign self-limiting infection. It probably occurs in the same manner in CF infants. Nonetheless, two cases of severe Pneumocystis primary infection mimicking PCP in CF infants have been reported, the genetic disease appearing in these circumstances as a risk factor of PCP while the host-pathogen interaction in older children and adults with pulmonary colonization remains to be clarified.
Prognosis of critically ill immunocompromised patients with virus-detected acute respiratory failure

Guillaume Dumas,Maxime Bertrand,Virginie Lemiale,Emmanuel Canet,François Barbier,Achille Kouatchet,Alexandre Demoule,Kada Klouche,Anne-Sophie Moreau,Laurent Argaud,Florent Wallet,Jean-Herlé Raphalen,Djamel Mokart,Fabrice Bruneel,Frédéric Pène,Elie Azoulay

DOI: https://doi.org/10.1186/s13613-023-01196-9

IF: 10.318

2023-10-15

Annals of Intensive Care

Abstract:Acute respiratory failure (ARF) is the leading cause of ICU admission. Viruses are increasingly recognized as a cause of pneumonia in immunocompromised patients, but epidemiologic data are scarce. We used the Groupe de Recherche en Réanimation Respiratoire en Onco-Hématologie 's database (2003–2017, 72 intensive care units) to describe the spectrum of critically ill immunocompromised patients with virus-detected ARF and to report their outcomes. Then, patients with virus-detected ARF were matched based on clinical characteristics and severity (1:3 ratio) with patients with ARF from other origins.

critical care medicine
ICU-acquired infections in immunocompromised patients

Louis Kreitmann,Julie Helms,Ignacio Martin-Loeches,Jorge Salluh,Garyphallia Poulakou,Frédéric Pène,Saad Nseir

DOI: https://doi.org/10.1007/s00134-023-07295-2

IF: 38.9

2024-01-11

Intensive Care Medicine

Abstract:Immunocompromised patients account for an increasing proportion of the typical intensive care unit (ICU) case-mix. Because of the increased availability of new drugs for cancer and auto-immune diseases, and improvement in the care of the most severely immunocompromised ICU patients (including those with hematologic malignancies), critically ill immunocompromised patients form a highly heterogeneous patient population. Furthermore, a large number of ICU patients with no apparent immunosuppression also harbor underlying conditions altering their immune response, or develop ICU-acquired immune deficiencies as a result of sepsis, trauma or major surgery. While infections are associated with significant morbidity and mortality in immunocompromised critically ill patients, little specific data are available on the incidence, microbiology, management and outcomes of ICU-acquired infections in this population. As a result, immunocompromised patients are usually excluded from trials and guidelines on the management of ICU-acquired infections. The most common ICU-acquired infections in immunocompromised patients are ventilator-associated lower respiratory tract infections (which include ventilator-associated pneumonia and tracheobronchitis) and bloodstream infections. Recently, several large observational studies have shed light on some of the epidemiological specificities of these infections—as well as on the dynamics of colonization and infection with multidrug-resistant bacteria—in these patients, and these will be discussed in this review. Immunocompromised patients are also at higher risk than non-immunocompromised hosts of fungal and viral infections, and the diagnostic and therapeutic management of these infections will be covered. Finally, we will suggest some important areas of future investigation.

critical care medicine
Clinical Outcomes and Risk Factor of Immune Checkpoint Inhibitors-Related Pneumonitis in Non-Small Cell Lung Cancer Patients with Chronic Obstructive Pulmonary Disease

Zhu Zeng,Jingjing Qu,Yake Yao,Fei Xu,Shan Lu,Pei Zhang,Yinan Yao,Ning Li,Jianying Zhou,Yuehong Wang

DOI: https://doi.org/10.1186/s12890-022-02190-w

IF: 3.1

2022-01-01

BMC Pulmonary Medicine

Abstract:Objectives: Chronic obstructive pulmonary disease (COPD) is the most common co-morbidity associated with non-small cell lung cancer (NSCLC) patients. Immune checkpoint inhibitors related pneumonitis (CIP) is a common immune-related adverse event that can be life-threatening. The study aims to evaluate the association of COPD with the incidence and outcome of CIP in NSCLC patients receiving immune checkpoint inhibitors (ICIs). Materials and methods: We retrospectively collected data from 122 patients diagnosed with NSCLC and treated with ICIs in our department. Baseline pulmonary function was performed in the whole cohort. The incidence, risk factors, treatment and outcome of CIP patients were evaluated. Furthermore, the efficacy of ICIs in patients with COPD was analyzed. Results: Nineteen patients (15.5%, 19/122) developed CIP during ICIs treatment, most patients with CIP were grade 1–2, and the incidence of CIP was comparable in patients with COPD and those without COPD (18.0% vs. 13.1%, P = 0.618). In addition, an increasing trend in the incidence of CIP among patients with pulmonary fibrosis on baseline chest CT scans (27.3% vs. 13.0%, P = 0.093). There is a longer progression-free survival in COPD patients than the non-COPD patients. Conclusion: Coexisting COPD did not predict the higher risk of CIP in NSCLC treated with ICIs therapy. Nevertheless, pre-existing pulmonary fibrosis on CT scan may increase the risk of CIP, close monitoring is advised in these patients during ICIs.
Pneumocystis jirovecii pneumonia in intensive care units: a multicenter study by ESGCIP and EFISG

Daniele Roberto Giacobbe,Silvia Dettori,Vincenzo Di Pilato,Erika Asperges,Lorenzo Ball,Enora Berti,Ola Blennow,Bianca Bruzzone,Laure Calvet,Federico Capra Marzani,Antonio Casabella,Sofia Choudaly,Anais Dartevel,Gennaro De Pascale,Gabriele Di Meco,Melissa Fallon,Louis-Marie Galerneau,Miguel Gallego,Mauro Giacomini,Adolfo González Sáez,Luise Hänsel,Giancarlo Icardi,Philipp Koehler,Katrien Lagrou,Tobias Lahmer,P Lewis White,Laura Magnasco,Anna Marchese,Cristina Marelli,Mercedes Marín-Arriaza,Ignacio Martin-Loeches,Armand Mekontso-Dessap,Malgorzata Mikulska,Alessandra Mularoni,Anna Nordlander,Julien Poissy,Giovanna Russelli,Alessio Signori,Carlo Tascini,Louis-Maxime Vaconsin,Joel Vargas,Antonio Vena,Joost Wauters,Paolo Pelosi,Jean-Francois Timsit,Matteo Bassetti,JIR-ICU investigators (collaborators),Critically Ill Patients Study Group of the European Society of Clinical Microbiology and Infectious Diseases (ESGCIP), and the Fungal Infection Study Group of the European Society of Clinical Microbiology and Infectious Diseases (EFISG),Matteo Cerchiaro,Mario Zaccarelli,Chiara Robba,Denise Battaglini,Iole Brunetti,Filippo Del Puente,Sara Mora,Sofía de la Villa,Maricela Valerio,Patricia Muñoz,Gianmarco Lombardi,Melania Cesarano,Veronica Gennenzi,Philippe Meersseman,Greet Hermans,Alexander Wilmer,Keyvan Razazi,Guillaume Carteaux,Nicolas de Prost,Oliver A Cornely,Danila Seidel,Ana Alastruey-Izquierdo,Jorge Garcia Borrega,Christine Bonnal,Etienne de Montmollin,Julien Dessajan,Mariaelena Ceresini,Francesco Mojoli,Ambra Vola,Cécile Garnaud,Emili Díaz,Oriol Gasch,Elena Prina,Sebastian Rasch,Miriam Dibos,Stefanie Haschka

DOI: https://doi.org/10.1186/s13054-023-04608-1

2023-08-24

Abstract:Background: Pneumocystis jirovecii pneumonia (PJP) is an opportunistic, life-threatening disease commonly affecting immunocompromised patients. The distribution of predisposing diseases or conditions in critically ill patients admitted to intensive care unit (ICU) and subjected to diagnostic work-up for PJP has seldom been explored. Materials and methods: The primary objective of the study was to describe the characteristics of ICU patients subjected to diagnostic workup for PJP. The secondary objectives were: (i) to assess demographic and clinical variables associated with PJP; (ii) to assess the performance of Pneumocystis PCR on respiratory specimens and serum BDG for the diagnosis of PJP; (iii) to describe 30-day and 90-day mortality in the study population. Results: Overall, 600 patients were included in the study, of whom 115 had presumptive/proven PJP (19.2%). Only 8.8% of ICU patients subjected to diagnostic workup for PJP had HIV infection, whereas hematological malignancy, solid tumor, inflammatory diseases, and solid organ transplants were present in 23.2%, 16.2%, 15.5%, and 10.0% of tested patients, respectively. In multivariable analysis, AIDS (odds ratio [OR] 3.31; 95% confidence interval [CI] 1.13-9.64, p = 0.029), non-Hodgkin lymphoma (OR 3.71; 95% CI 1.23-11.18, p = 0.020), vasculitis (OR 5.95; 95% CI 1.07-33.22, p = 0.042), metastatic solid tumor (OR 4.31; 95% CI 1.76-10.53, p = 0.001), and bilateral ground glass on CT scan (OR 2.19; 95% CI 1.01-4.78, p = 0.048) were associated with PJP, whereas an inverse association was observed for increasing lymphocyte cell count (OR 0.64; 95% CI 0.42-1.00, p = 0.049). For the diagnosis of PJP, higher positive predictive value (PPV) was observed when both respiratory Pneumocystis PCR and serum BDG were positive compared to individual assay positivity (72% for the combination vs. 63% for PCR and 39% for BDG). Cumulative 30-day mortality and 90-day mortality in patients with presumptive/proven PJP were 52% and 67%, respectively. Conclusion: PJP in critically ill patients admitted to ICU is nowadays most encountered in non-HIV patients. Serum BDG when used in combination with respiratory Pneumocystis PCR could help improve the certainty of PJP diagnosis.
Covid-19-associated pulmonary aspergillosis in mechanically ventilated patients: incidence and outcome in a French multicenter observational cohort (APICOVID)

Luc Desmedt,Matthieu Raymond,Aurélie Le Thuaut,Pierre Asfar,Cédric Darreau,Florian Reizine,Gwenhaël Colin,Johann Auchabie,Julien Lorber,Béatrice La Combe,Pierre Kergoat,Baptiste Hourmant,Agathe Delbove,Aurélien Frérou,Jean Morin,Pierre Yves Ergreteau,Philippe Seguin,Maëlle Martin,Jean Reignier,Jean-Baptiste Lascarrou,Emmanuel Canet

DOI: https://doi.org/10.1186/s13613-023-01229-3

IF: 10.318

2024-01-31

Annals of Intensive Care

Abstract:Recent studies identified coronavirus disease 2019 (COVID-19) as a risk factor for invasive pulmonary aspergillosis (IPA) but produced conflicting data on IPA incidence and impact on patient outcomes. We aimed to determine the incidence and outcomes of COVID-19-associated pulmonary aspergillosis (CAPA) in mechanically ventilated patients.

critical care medicine
Diagnosis and treatment of pneumocystis pneumonia - a review article

Tarig Eltoum Yagoub Fadelelmoula

DOI: https://doi.org/10.55214/25768484.v8i6.2032

2024-09-28

Edelweiss Applied Science and Technology

Abstract:This study aims to comprehensively evaluate the literature on recent advances in the diagnosis and treatment of Pneumocystis Pneumonia (PCP). A thorough review of relevant literature was conducted. Data were sourced from electronic databases such as PubMed, Scopus, Google Scholar, and Medline, focusing on articles published within the last ten years. The review included 41 articles. The diagnosis of PCP has evolved with the development of molecular techniques, advanced imaging modalities, and artificial intelligence models. Trimethoprim-sulfamethoxazole (TMP-SMX) remains the mainstay of treatment. Corticosteroid adjunctive therapy (CAT) has demonstrated efficacy in improving outcomes, while emerging research suggests a potential role for immunomodulatory agents. Chemoprophylaxis with TMP-SMX remains the main stay of prevention in populations at risk. Despite advances in diagnostic technologies, treatment options for PCP have largely remained unchanged. There are currently no vaccines, and chemoprophylaxis remains the mainstay of prevention. Practical Immediate treatment is essential. New ELISA techniques are viable, while real-time PCR proves superior to nested PCR. Clinical judgment plays a critical role in supporting laboratory diagnoses. High-resolution CT scans may be warranted for evaluating immunosuppressed patients with suspected pneumonia when chest X-rays appear normal. Radiomics can assist in distinguishing PCP from other types of pneumonia in non-HIV patients. Trimethoprim-sulfamethoxazole remains the preferred treatment, with alternative options including dapsone with trimethoprim, clindamycin with primaquine, atovaquone, or pentamidine. Corticosteroid adjunct therapy (CAT) is beneficial in treating PCP, and chemoprophylaxis is essential for high-risk populations.

Pneumocystis pneumonia in French intensive care units in 2013–2019: mortality and immunocompromised conditions

Trends in the Epidemiology of Pneumocystis Pneumonia in Immunocompromised Patients without HIV Infection

Characteristics and Prognosis Factors of Pneumocystis jirovecii Pneumonia According to Underlying Disease: A Retrospective Multicenter Study

Severe Community-Acquired Pneumonia in Immunocompromised Patients

Pneumocystis jirovecii pneumonia in non-HIV patients: need for a more extended prophylaxis

Pneumocystis pneumonia in intensive care: clinical spectrum, prophylaxis patterns, antibiotic treatment delay impact, and role of corticosteroids. A French multicentre prospective cohort study

Outcome and prognostic factors of Pneumocystis jirovecii pneumonia in immunocompromised adults: a prospective observational study

Clinical characteristics of Pneumocystis carinii pneumonia in immunocompromised patients

Epidemiology, Clinical Characteristics, and Diagnostic Testing Practices for Pneumocystis Pneumonia–Associated Hospitalizations, United States, 2019–2022

Clinical course and prognostic factors of Pneumocystis pneumonia with respiratory failure in non-HIV patients

Community-acquired Klebsiella pneumoniae pneumonia in ICU: a multicenter retrospective study

Hospital Burden of All-Cause Pneumonia and Nonbacteremic Pneumococcal Pneumonia in Adults in France Between 2013 and 2019

Incidence, caractéristiques et survie des patients présentant une pneumocystose en oncologie solide

Impact of direct ICU admission of pneumococcal meningitis in France: a retrospective analysis of a French medico-administrative (PMSI) database

Pneumocystis jirovecii in Patients With Cystic Fibrosis: A Review

Prognosis of critically ill immunocompromised patients with virus-detected acute respiratory failure

ICU-acquired infections in immunocompromised patients

Clinical Outcomes and Risk Factor of Immune Checkpoint Inhibitors-Related Pneumonitis in Non-Small Cell Lung Cancer Patients with Chronic Obstructive Pulmonary Disease

Pneumocystis jirovecii pneumonia in intensive care units: a multicenter study by ESGCIP and EFISG

Covid-19-associated pulmonary aspergillosis in mechanically ventilated patients: incidence and outcome in a French multicenter observational cohort (APICOVID)

Diagnosis and treatment of pneumocystis pneumonia - a review article